Trilostane
From Wikipedia, the free encyclopedia
 |
|
|
Trilostane
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | H02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H27NO3 |
| Mol. mass | 329.433 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 8 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Withdrawn (U.S.) |
| Routes | ? |
Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome.[1] It was withdrawn from the United States market in April 1994.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
[edit] References
- ^ Komanicky P, Spark RF, Melby JC. (1978). "Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis". Journal of Clinical Endocrinology and Metabolism 47 (5): 1042–1051. PMID 233687.
|
|||||||||||
